Phase 4 Study of Laybon Tab. in Knee Osteoarthritis

Summary

This Phase 4, multicenter, randomized, double-blind, active-controlled, parallel study aims to evaluate the non-inferiority of Laybon Tab. compared to Layla Tab. (PMG Pharm Co., Ltd.) in patients with knee osteoarthritis. Participants will receive either Laybon Tab. or Layla Tab. for 8 weeks. The primary outcome is the change in knee pain during activity, assessed by a 100 mm pain VAS over the previous 24 hours.

Timeline

Start

2025-12

Primary completion

2027-12

Completion

2028-03

Drugs

Indications